Table 3.
Demographics and clinical features of uveitis patients treated with certolizumab pegol in previous reports.
| Author (year) | # of Cases | Gender | Age (yrs) | Type of Uveitis | Etiology | Treatment Duration (months) | Response to Therapy |
|---|---|---|---|---|---|---|---|
| Llorenc et al.5 | 7 | 4 males 3 females |
42.4 ± 8.8 | AU PU AU + SCL PAN |
idiopathic BD AS PsA CD RP |
10.4 ± 4.8 | 5 Yes 2 No |
| Tlucek et al.6 | 1 | female | 47 | SCL | RA | 6 | Yes |
| Maiz Alonso et al.7 | 1 | male | 33 | AU | AS + CD | 25 | Yes |
| Hernández M et al.8 | 13 | 10 males 3 females |
49.5 ± 11.7 | AU IU PAN |
AS PsA IBD |
17.8 ± 9.9 | 10 Yes 3 No |
| Current case series | 3 | 2 males 1 female |
19.3 ± 2 | AU IU |
idiopathic JIA CD |
32.3 ± 18.1 | 3 Yes |
AU, anterior uveitis; Yrs, years; PU, posterior uveitis; IU, intermediate uveitis; PAN, panuveitis; SCL, scleritis; BD, Behçet's disease; AS, ankylosing spondylitis; PsA, psoriatic arthritis; CD, Crohn's disease; JIA, juvenile idiopathic arthritis; RA, Rheumatoid arthritis; RP, relapsing polychondritis; IBD, inflammatory bowel disease.